

# Trial of Anifrolumab in Active Systemic Lupus Erythem

New England Journal of Medicine

382, 211-221

DOI: [10.1056/nejmoa1912196](https://doi.org/10.1056/nejmoa1912196)

Citation Report

#	ARTICLE	IF	CITATIONS
1	A Successful Trial for Lupus – How Good Is Good Enough?. New England Journal of Medicine, 2020, 382, 287-288.	13.9	15
2	Biologic therapies for systemic lupus erythematosus: where are we now?. Current Opinion in Rheumatology, 2020, 32, 597-608.	2.0	8
3	Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis. Current Opinion in Rheumatology, 2020, 32, 609-616.	2.0	12
4	A Comprehensive Review of Biological Agents for Lupus: Beyond Single Target. Frontiers in Immunology, 2020, 11, 539797.	2.2	11
5	Anifrolumab in lupus: the promise and the caution – Author's reply. Lancet Rheumatology, The, 2020, 2, e462.	2.2	0
6	First-in-Human study of JNJ-55920839 in healthy volunteers and patients with systemic lupus erythematosus: a randomised placebo-controlled phase 1 trial. Lancet Rheumatology, The, 2020, 2, e613-e622.	2.2	6
7	Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors. International Journal of Molecular Sciences, 2020, 21, 7767.	1.8	18
8	Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage. Arthritis Care and Research, 2020, 72, 27-46.	1.5	33
9	Anifrolumab in lupus: the promise and the caution. Lancet Rheumatology, The, 2020, 2, e461-e462.	2.2	0
10	Targeting interferon I in SLE: a promising new perspective. Lancet Rheumatology, The, 2020, 2, e581-e582.	2.2	2
11	Systemic lupus erythematosus (SLE): emerging therapeutic targets. Expert Opinion on Therapeutic Targets, 2020, 24, 1283-1302.	1.5	23
12	Recent advances in understanding pathogenesis and therapeutic strategies of Systemic Lupus Erythematosus. International Immunopharmacology, 2020, 89, 107028.	1.7	17
13	Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. Lupus Science and Medicine, 2020, 7, e000424.	1.1	35
15	The design, synthesis and evaluation of 2-aminobenzoxazole analogues as potent and orally efficacious ChemR23 inhibitors. Bioorganic and Medicinal Chemistry, 2020, 28, 115622.	1.4	7
16	Lupus erythematosus 2020. Medicina Clínica (English Edition), 2020, 155, 494-501.	0.1	3
17	Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials. Zeitschrift Fur Rheumatologie, 2020, 80, 988-994.	0.5	5
18	Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways. Frontiers in Immunology, 2020, 11, 606456.	2.2	98
19	Type I interferon in the pathogenesis of systemic lupus erythematosus. Current Opinion in Immunology, 2020, 67, 87-94.	2.4	104

#	ARTICLE	IF	CITATIONS
20	The innate immune system and cell death in autoinflammatory and autoimmune disease. <i>Current Opinion in Immunology</i> , 2020, 67, 95-105.	2.4	39
21	The Role of Cutaneous Type I IFNs in Autoimmune and Autoinflammatory Diseases. <i>Journal of Immunology</i> , 2020, 205, 2941-2950.	0.4	8
23	Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity. <i>Nature Communications</i> , 2020, 11, 6149.	5.8	71
24	Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders. <i>Frontiers in Immunology</i> , 2020, 11, 592639.	2.2	1
25	Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. <i>Rheumatology</i> , 2020, 59, v69-v81.	0.9	69
26	The management of neuropsychiatric lupus in the 21st century: still so many unmet needs?. <i>Rheumatology</i> , 2020, 59, v52-v62.	0.9	52
27	Expert Perspective: An Evidence-Based Approach to Refractory Cutaneous Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020, 72, 1777-1785.	2.9	10
28	Systemic lupus erythematosus: an expert insight into emerging therapy agents in preclinical and early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1151-1162.	1.9	6
29	Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1191-1201.	1.6	19
30	Type I interferon antagonists in clinical development for lupus. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1025-1041.	1.9	14
31	Interferon blockade in systemic lupus erythematosus: Light at the end of the tunnel for novel therapies for lupus?. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 995-997.	0.9	0
32	Lupus eritematoso sist�mico 2020. <i>Medicina Cl�nica</i> , 2020, 155, 494-501.	0.3	26
33	European League Against Rheumatism (EULAR) recommendations and EULAR/American College of Rheumatology criteria�� documenting progress in lupus. <i>Rheumatology</i> , 2020, 60, 2976-2978.	0.9	1
34	Janus Kinase Inhibition and SLE: Is this a Plausible Treatment Option for SLE?. <i>Current Treatment Options in Rheumatology</i> , 2020, 6, 406-417.	0.6	3
35	String of successful trials in SLE: have we cracked the code?. <i>Lupus Science and Medicine</i> , 2020, 7, e000380.	1.1	6
36	Systemic lupus erythematosus: year in review 2019. <i>Chinese Medical Journal</i> , 2020, 133, 2189-2196.	0.9	20
37	Diagnostic and prognostic markers and treatment of connective tissue disease-associated pulmonary arterial hypertension: current recommendations and recent advances. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 993-1004.	1.3	7
38	The myeloid type I interferon response to myocardial infarction begins in bone marrow and is regulated by Nrf2-activated macrophages. <i>Science Immunology</i> , 2020, 5, .	5.6	43

#	ARTICLE	IF	CITATIONS
39	Biologics targeting type I interferons in SLE: A meta-analysis and systematic review of randomised controlled trials. <i>Lupus</i> , 2020, 29, 1845-1853.	0.8	11
40	Phoenix from the flames: Rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis. <i>Autoimmunity Reviews</i> , 2020, 19, 102668.	2.5	35
41	Structural integrity with functional plasticity: what type I IFN receptor polymorphisms reveal. <i>Journal of Leukocyte Biology</i> , 2020, 108, 909-924.	1.5	8
42	Understanding and adjusting for the selection bias from a proof-of-concept study to a more confirmatory study. <i>Statistics in Medicine</i> , 2020, 39, 4593-4604.	0.8	3
43	An Update on the Pathogenesis of Cutaneous Lupus Erythematosus and Its Role in Clinical Practice. <i>Current Rheumatology Reports</i> , 2020, 22, 69.	2.1	14
44	Tripterygium and its plant extraction for systemic lupus erythematosus. <i>Medicine (United States)</i> , 2020, 99, e21909.	0.4	4
45	Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2020, 383, 1149-1155.	13.9	178
46	LncRNA <i>Malat1</i> inhibition of TDP43 cleavage suppresses IRF3-initiated antiviral innate immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 23695-23706.	3.3	99
47	Multiple pathways of type 1 interferon production in lupus: the case for amlexanox. <i>Rheumatology</i> , 2020, 59, 3980-3982.	0.9	1
48	A wide perspective of targeted therapies for precision medicine in autoimmune diseases. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 447-453.	0.4	3
49	Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2096926.	1.2	16
50	Candidate drug replacements for quinacrine in cutaneous lupus erythematosus. <i>Lupus Science and Medicine</i> , 2020, 7, e000430.	1.1	7
51	Treatment targets in SLE: remission and low disease activity state. <i>Rheumatology</i> , 2020, 59, v19-v28.	0.9	26
53	Plasmacytoid dendritic cell biology and its role in immune-mediated diseases. <i>Clinical and Translational Immunology</i> , 2020, 9, e1139.	1.7	70
54	Systemic lupus erythematosus and risk of infection. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 527-538.	1.3	44
55	Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New. <i>Rheumatology and Therapy</i> , 2020, 7, 433-446.	1.1	100
56	The history of lupus throughout the ages. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1361-1369.	0.6	12
57	Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3463.	1.8	26

#	ARTICLE	IF	CITATIONS
58	Management of cardiovascular disease in patients with systemic lupus erythematosus. Expert Opinion on Pharmacotherapy, 2020, 21, 1617-1627.	0.9	16
59	Are lupus animal models useful for understanding and developing new therapies for human SLE?. Journal of Autoimmunity, 2020, 112, 102490.	3.0	13
60	Efficacy of anifrolumab in systemic lupus erythematosus: a critical analysis of the TULIP trials. Lupus, 2020, 29, 1002-1003.	0.8	3
61	An Update on the Diagnosis and Management of Lupus Nephritis. Current Rheumatology Reports, 2020, 22, 30.	2.1	21
62	Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases. Clinical Reviews in Allergy and Immunology, 2020, 59, 248-272.	2.9	81
63	The regulation and pharmacological modulation of immune complex induced type III IFN production by plasmacytoid dendritic cells. Arthritis Research and Therapy, 2020, 22, 130.	1.6	14
64	Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies. Cancers, 2020, 12, 1475.	1.7	69
65	Low Density Neutrophils in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2020, 72, 1587-1595.	2.9	42
66	A Tale of Two Trials. Arthritis and Rheumatology, 2020, 72, 1256-1257.	2.9	3
67	Biosimilars. Lupus, 2020, 29, 525-532.	0.8	3
68	State-of-the-art treatment of systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2020, 23, 465-471.	0.9	85
69	Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy. Nature Reviews Rheumatology, 2020, 16, 255-267.	3.5	74
71	Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations. Immunotherapy, 2020, 12, 275-286.	1.0	16
72	Taurine Metabolism Aggravates the Progression of Lupus by Promoting the Function of Plasmacytoid Dendritic Cells. Arthritis and Rheumatology, 2020, 72, 2106-2117.	2.9	13
73	Using Clinical Cases to Restore Basic Science Immunology Knowledge in Physicians and Senior Medical Students. Frontiers in Immunology, 2020, 11, 1756.	2.2	2
75	B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice. Frontiers in Medicine, 2020, 7, 316.	1.2	50
76	Clinical trials and novel therapeutics in dermatomyositis. Expert Opinion on Emerging Drugs, 2020, 25, 213-228.	1.0	9
77	Biologics in the treatment of skin and rheumatologic diseases. Journal of Allergy and Clinical Immunology, 2020, 145, 1138-1141.	1.5	7

#	ARTICLE	IF	CITATIONS
78	New insights into IFN- $\beta$ in rheumatoid arthritis: role in the era of JAK inhibitors. <i>Immunological Medicine</i> , 2020, 43, 72-78.	1.4	51
79	Update on the cellular and molecular aspects of lupus nephritis. <i>Clinical Immunology</i> , 2020, 216, 108445.	1.4	28
80	Type I interferon. <i>Cytokine</i> , 2020, 132, 155109.	1.4	1
81	Treatment of cutaneous lupus erythematosus: current approaches and future strategies. <i>Current Opinion in Rheumatology</i> , 2020, 32, 208-214.	2.0	22
82	Rare genetic variants in systemic autoimmunity. <i>Immunology and Cell Biology</i> , 2020, 98, 490-499.	1.0	8
83	A Spectrum of Skin Disease: How <i>Staphylococcus aureus</i> Colonization, Barrier Dysfunction, and Cytokines Shape the Skin. <i>Journal of Investigative Dermatology</i> , 2020, 140, 941-944.	0.3	1
84	Anifrolumab in Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2020, 382, 1665-1666.	13.9	4
86	Which is the best SLE activity index for clinical trials?. <i>Modern Rheumatology</i> , 2021, 31, 20-28.	0.9	24
87	Management of Severe Refractory Systemic Lupus Erythematosus: Real-World Experience and Literature Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 60, 17-30.	2.9	15
88	Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis. <i>Rheumatology</i> , 2021, 60, 73-80.	0.9	3
89	Interferon-stimulated GTPases in autoimmune and inflammatory diseases: promising role for the guanylate-binding protein (GBP) family. <i>Rheumatology</i> , 2021, 60, 494-506.	0.9	17
90	Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren's Syndrome: A Randomized Clinical Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 143-150.	2.9	35
91	Reply. <i>Arthritis and Rheumatology</i> , 2021, 73, 176-178.	2.9	0
92	Kidney outcomes for children with lupus nephritis. <i>Pediatric Nephrology</i> , 2021, 36, 1377-1385.	0.9	53
93	Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies. <i>Trends in Molecular Medicine</i> , 2021, 27, 152-171.	3.5	34
94	Interferon activation status underlies higher antibody response to viral antigens in patients with systemic lupus erythematosus receiving no or light treatment. <i>Rheumatology</i> , 2021, 60, 1445-1455.	0.9	4
95	Anti-IFN- $\alpha$ R Mabs for the treatment of systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 519-528.	1.4	9
96	Update in the diagnosis and management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 14-25.	0.5	312

#	ARTICLE	IF	CITATIONS
97	Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 109-117.	0.5	35
98	Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus. <i>Biologicals</i> , 2021, 69, 1-14.	0.5	13
99	Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet Rheumatology</i> , The, 2021, 3, e101-e110.	2.2	9
100	Subcutaneous anifrolumab for SLE: a new step forward?. <i>Lancet Rheumatology</i> , The, 2021, 3, e84-e85.	2.2	0
101	B cell depletion therapies in autoimmune disease: advances and mechanistic insights. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 179-199.	21.5	296
102	COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. <i>Translational Research</i> , 2021, 232, 13-36.	2.2	69
103	Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 49-71.	1.6	15
104	Quantitative proteomics of epigenetic histone modifications in MCF-7 cells under estradiol stimulation. <i>Analytical Methods</i> , 2021, 13, 469-476.	1.3	0
105	Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. <i>Modern Rheumatology</i> , 2021, 31, 1-12.	0.9	52
106	Partial Protection From Lupus-Like Disease by B-Cell Specific Type I Interferon Receptor Deficiency. <i>Frontiers in Immunology</i> , 2020, 11, 616064.	2.2	10
107	The expression of interferon-stimulated genes (interferon "signature") in patients with rheumatoid arthritis (Preliminary results). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 58, 673-677.	0.2	1
108	Pipeline therapies and future drug development. , 2021, , 661-671.		0
109	Antibodies to watch in 2021. <i>MAbs</i> , 2021, 13, 1860476.	2.6	237
110	Challenges of systemic lupus clinical trials. , 2021, , 673-682.		0
111	New developments in systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, vi21-vi28.	0.9	16
112	Type I Interferon-Activated STAT4 Regulation of Follicular Helper T Cell-Dependent Cytokine and Immunoglobulin Production in Lupus. <i>Arthritis and Rheumatology</i> , 2021, 73, 478-489.	2.9	23
113	Studiendesign/Protokolle und Therapiesteuerung in der pädiatrischen Rheumatologie. <i>Springer Reference Medizin</i> , 2021, , 1-19.	0.0	0
114	The peptide symporter SLC15a4 is essential for the development of systemic lupus erythematosus in murine models. <i>PLoS ONE</i> , 2021, 16, e0244439.	1.1	17

#	ARTICLE	IF	CITATIONS
115	C-Reactive Protein Levels in Systemic Lupus Erythematosus Are Modulated by the Interferon Gene Signature and CRP Gene Polymorphism rs1205. <i>Frontiers in Immunology</i> , 2020, 11, 622326.	2.2	26
116	Type I interferons as key players in pancreatic $\beta$ -cell dysfunction in type 1 diabetes. <i>International Review of Cell and Molecular Biology</i> , 2021, 359, 1-80.	1.6	19
117	Metrics and Outcomes of SLE Clinical Trials. , 2021, , 371-390.		0
118	Weiterentwicklung in der Therapie rheumatischer Erkrankungen bei Kindern und Jugendlichen. <i>Springer Reference Medizin</i> , 2021, , 1-19.	0.0	0
120	Recent Advances in Lupus B Cell Biology: PI3K, IFN $\beta$ , and Chromatin. <i>Frontiers in Immunology</i> , 2020, 11, 615673.	2.2	17
121	Immune Cellâ€™Stromal Circuitry in Lupus Photosensitivity. <i>Journal of Immunology</i> , 2021, 206, 302-309.	0.4	11
122	Immune Dysfunction and Drug Targets in Autoinflammatory Syndromes. , 2021, , .		0
124	S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN- $\alpha$ ) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100093.	2.0	3
125	SLE non-coding genetic risk variant determines the epigenetic dysfunction of an immune cell specific enhancer that controls disease-critical microRNA expression. <i>Nature Communications</i> , 2021, 12, 135.	5.8	48
126	Dermatomyositis bei Kindern und Jugendlichen. <i>Springer Reference Medizin</i> , 2021, , 1-37.	0.0	0
128	Immune-Related Adverse Events with Other Cancer Immunotherapies. , 2021, , 255-269.		1
129	Making Sense of Intracellular Nucleic Acid Sensing in Type I Interferon Activation in Sjögrenâ€™s Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 532.	1.0	7
130	Bite of the wolf: innate immune responses propagate autoimmunity in lupus. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	54
132	The Role of Nucleases and Nucleic Acid Editing Enzymes in the Regulation of Self-Nucleic Acid Sensing. <i>Frontiers in Immunology</i> , 2021, 12, 629922.	2.2	18
133	Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. <i>Lupus Science and Medicine</i> , 2021, 8, e000464.	1.1	45
134	Interferon $\alpha$ Enhances B Cell Activation Associated With FOXM1 Induction: Potential Novel Therapeutic Strategy for Targeting the Plasmablasts of Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2020, 11, 498703.	2.2	23
135	Research in practice: Disturbance in intracellular nucleic acid metabolism promotes lupus erythematosus. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 209-213.	0.4	3
136	Exposureâ€™response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 5854-5862.	0.9	11

#	ARTICLE	IF	CITATIONS
137	Potent and Selective Knockdown of Tyrosine Kinase 2 by Antisense Oligonucleotides. <i>ImmunoHorizons</i> , 2021, 5, 70-80.	0.8	6
138	RNA tape sampling in cutaneous lupus erythematosus discriminates affected from unaffected and healthy volunteer skin. <i>Lupus Science and Medicine</i> , 2021, 8, e000428.	1.1	6
139	Type I interferons affect the metabolic fitness of CD8+ T cells from patients with systemic lupus erythematosus. <i>Nature Communications</i> , 2021, 12, 1980.	5.8	56
141	Coronavirus disease 2019 (COVID-19) and autoimmunity. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 5-30.	0.2	28
142	Treatment of neuropsychiatric systemic lupus erythematosus: clinical challenges and future perspectives. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 317-329.	1.3	10
143	Autoantibodies Targeting Intracellular and Extracellular Proteins in Autoimmunity. <i>Frontiers in Immunology</i> , 2021, 12, 548469.	2.2	45
144	The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. <i>Annals of Translational Medicine</i> , 2021, 9, 431-431.	0.7	15
146	EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice. <i>Frontiers in Immunology</i> , 2021, 12, 653989.	2.2	17
147	What's New in the Treatment of Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , 2021, 8, 655100.	1.2	31
148	Neutrophils in the Pathogenesis of Rheumatoid Arthritis and Systemic Lupus Erythematosus: Same Foe Different M.O.. <i>Frontiers in Immunology</i> , 2021, 12, 649693.	2.2	90
149	Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally. <i>Arthritis Care and Research</i> , 2022, 74, 1623-1630.	1.5	3
150	Belimumab: a step forward in the treatment of systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 563-573.	1.4	9
152	Type I Interferonopathies in Children: An Overview. <i>Frontiers in Pediatrics</i> , 2021, 9, 631329.	0.9	42
153	15â€¦Strategies for minimizing corticosteroid exposure in SLE. , 2021, , .		0
154	Type I interferon activation and endothelial dysfunction in caveolin-1 insufficiency-associated pulmonary arterial hypertension. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	19
155	Multi-â€œcell type gene coexpression network analysis reveals coordinated interferon response and cross-â€œcell type correlations in systemic lupus erythematosus. <i>Genome Research</i> , 2021, 31, 659-676.	2.4	23
156	Investigation of type I interferon responses in ANCA-associated vasculitis. <i>Scientific Reports</i> , 2021, 11, 8272.	1.6	6
157	Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention. <i>Inflammation</i> , 2021, 44, 1663-1682.	1.7	21

#	ARTICLE	IF	CITATIONS
158	Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study. <i>Rheumatology</i> , 2021, 60, 5194-5204.	0.9	16
159	HDAC1 potentiates CD4 <sup>+</sup> T cell activation by inhibiting miR-124 and promoting IRF1 in systemic lupus erythematosus. <i>Cellular Immunology</i> , 2021, 362, 104284.	1.4	8
160	Interferon lambda in inflammation and autoimmune rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2021, 17, 349-362.	3.5	42
161	What Does it Mean to be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of 2 Phase 3 Trials. <i>Arthritis and Rheumatology</i> , 2021, 73, 2059-2068.	2.9	12
162	Advances in Lupus Nephritis Pathogenesis: From Bench to Bedside. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3766.	1.8	26
163	Type I Interferons in Systemic Autoimmune Diseases: Distinguishing Between Afferent and Efferent Functions for Precision Medicine and Individualized Treatment. <i>Frontiers in Pharmacology</i> , 2021, 12, 633821.	1.6	21
164	Type I Interferon Production of Plasmacytoid Dendritic Cells under Control. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4190.	1.8	40
165	The winter of my discontent. <i>Turkish Archives of Pediatrics</i> , 2021, 56, 177-178.	0.5	0
166	A STING antagonist modulating the interaction with STIM1 blocks ER-to-Golgi trafficking and inhibits lupus pathology. <i>EBioMedicine</i> , 2021, 66, 103314.	2.7	31
167	Transcriptomic studies of systemic lupus erythematosus. <i>Inflammation and Regeneration</i> , 2021, 41, 11.	1.5	8
168	Measuring IFN activity in suspected SLE: a valuable step?. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 545-548.	1.3	3
169	The role of innate immunity in myasthenia gravis. <i>Autoimmunity Reviews</i> , 2021, 20, 102800.	2.5	3
170	Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. <i>Lupus</i> , 2021, 30, 1254-1263.	0.8	36
171	The neurology of lupus. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117419.	0.3	7
172	Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	50
173	A molecular signature as a guidance for glucocorticoid: are we there yet?. <i>Lancet Rheumatology</i> , The, 2021, 3, e315-e317.	2.2	1
174	What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts. <i>Lupus Science and Medicine</i> , 2021, 8, e000506.	1.1	1
175	Cutaneous Manifestations of "Lupus", Systemic Lupus Erythematosus and Beyond. <i>International Journal of Rheumatology</i> , 2021, 2021, 1-19.	0.9	16

#	ARTICLE	IF	CITATIONS
176	Problems of early diagnosis of systemic lupus erythematosus during the COVID-19 pandemic. Nauchno-Prakticheskaya Revmatologiya, 2021, 59, 119-128.	0.2	13
177	Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: a cross-sectional and in-vitro study. Lancet Rheumatology, The, 2021, 3, e357-e370.	2.2	14
178	B cells in primary antiphospholipid syndrome: Review and remaining challenges. Autoimmunity Reviews, 2021, 20, 102798.	2.5	10
179	Acquired White Oral Lesions with Specific Patterns: Oral Lichen Planus and Lupus Erythematosus. Dermatology Practical and Conceptual, 2021, 11, 2021074.	0.5	3
180	Current Status of the Evaluation and Management of Lupus Patients and Future Prospects. Frontiers in Medicine, 2021, 8, 682544.	1.2	5
181	Crosstalk between Interleukin-1 $\beta$ and Type I Interferons Signaling in Autoinflammatory Diseases. Cells, 2021, 10, 1134.	1.8	7
182	Monogenic Autoinflammatory Diseases: State of the Art and Future Perspectives. International Journal of Molecular Sciences, 2021, 22, 6360.	1.8	28
183	Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nature Communications, 2021, 12, 3391.	5.8	93
184	In Vitro Effects of Sulforaphane on Interferon-Driven Inflammation and Exploratory Evaluation in Two Healthy Volunteers. Molecules, 2021, 26, 3602.	1.7	2
185	Treatment Update in Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2021, 47, 513-530.	0.8	6
186	Interferons in Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2021, 47, 297-315.	0.8	9
187	Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus. Frontiers in Immunology, 2021, 12, 688753.	2.2	12
188	Meant to B: B cells as a therapeutic target in systemic lupus erythematosus. Journal of Clinical Investigation, 2021, 131, .	3.9	27
189	Systemic Lupus Erythematosus Outcome Measures for Systemic Lupus Erythematosus Clinical Trials. Rheumatic Disease Clinics of North America, 2021, 47, 415-426.	0.8	4
190	Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus. Frontiers in Immunology, 2021, 12, 654701.	2.2	13
191	Updates on Clinical Trials in Systemic Lupus Erythematosus. Current Rheumatology Reports, 2021, 23, 57.	2.1	2
192	Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models. Arthritis Research and Therapy, 2021, 23, 203.	1.6	3
193	Bispecific antibodies: A guide to model informed drug discovery and development. Heliyon, 2021, 7, e07649.	1.4	3

#	ARTICLE	IF	CITATIONS
194	Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 601-611.	0.6	3
195	Biomarkers Associated with Organ-Specific Involvement in Juvenile Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7619.	1.8	13
196	Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease. <i>Nature Communications</i> , 2021, 12, 4379.	5.8	24
197	Cluster of highly expressed interferon-stimulated genes associate more with African ancestry than disease activity in patients with systemic lupus erythematosus. A systematic review of cross-sectional studies. <i>Translational Research</i> , 2021, 238, 63-75.	2.2	15
198	Chinese Herbal Medicine for Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis of Randomized, Placebo-Controlled Trials. <i>Chinese Journal of Integrative Medicine</i> , 2021, 27, 778-787.	0.7	10
199	The landscape of systemic lupus erythematosus in Brazil: An expert panel review and recommendations. <i>Lupus</i> , 2021, 30, 1684-1695.	0.8	7
200	Plasmacytoid Dendritic Cells as a New Therapeutic Target for Autoimmune Pancreatitis and IgG4-Related Disease. <i>Frontiers in Immunology</i> , 2021, 12, 713779.	2.2	6
201	Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR). <i>Lupus Science and Medicine</i> , 2021, 8, e000513.	1.1	8
202	Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis—a spin-off study of the NORD-STAR randomized clinical trial. <i>Arthritis Research and Therapy</i> , 2021, 23, 189.	1.6	5
203	Systemic lupus erythematosus: a clinical update. <i>Internal Medicine Journal</i> , 2021, 51, 1219-1228.	0.5	2
204	Erythroid mitochondrial retention triggers myeloid-dependent type I interferon in human SLE. <i>Cell</i> , 2021, 184, 4464-4479.e19.	13.5	90
205	Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 1835-1846.	2.9	59
206	Importance of lymphocyte-stromal cell interactions in autoimmune and inflammatory rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2021, 17, 550-564.	3.5	27
207	Autophagy receptor CCDC50 tunes the STING-mediated interferon response in viral infections and autoimmune diseases. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2358-2371.	4.8	26
208	B-Cell Compartmental Features and Molecular Basis for Therapy in Autoimmune Disease. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	20
209	Resolution of the Expert Council «The role of type I interferon inhibitor in the treatment of patients with systemic lupus erythematosus». <i>Sovremennaya Revmatologiya</i> , 2021, 15, 126-128.	0.1	0
211	Innovative Trials and New Opportunities in SLE. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 481-499.	0.8	2
212	Clinician-reported outcome measures in lupus trials: a problem worth solving. <i>Lancet Rheumatology</i> , 2021, 3, e595-e603.	2.2	13

#	ARTICLE	IF	CITATIONS
213	Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA). <i>Rheumatology</i> , 2022, 61, 926-935.	0.9	21
214	What Did Not Work: The Drug or the Trial?. <i>Arthritis and Rheumatology</i> , 2021, 73, 1773-1775.	2.9	6
215	Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic Lupus Erythematosus. <i>Clinical Immunology</i> , 2021, 229, 108765.	1.4	29
216	IFN- $\gamma$ Is a Rheostat for Development of Psoriasisiform Inflammation. <i>Journal of Investigative Dermatology</i> , 2022, 142, 155-165.e3.	0.3	12
218	Type I interferon detection in autoimmune diseases: challenges and clinical applications. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 883-903.	1.3	6
220	Regulation of B Cell Responses in SLE by Three Classes of Interferons. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10464.	1.8	6
221	Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. <i>Rheumatology</i> , 2022, 61, 2413-2423.	0.9	25
222	Anifrolumab: First Approval. <i>Drugs</i> , 2021, 81, 1795-1802.	4.9	38
223	Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 1900-1910.	0.9	10
224	Neuropsychiatric Systemic Lupus Erythematosus: A 2021 Update on Diagnosis, Management, and Current Challenges. <i>Cureus</i> , 2021, 13, e17969.	0.2	23
226	Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 239-261.	2.9	20
227	From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift?. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 15-19.	0.5	24
228	Serum interferon- $\gamma$ measured by single-molecule array associates with systemic disease manifestations in Sjögren's syndrome. <i>Rheumatology</i> , 2022, 61, 2156-2166.	0.9	8
229	Anti-TRIM21 antibody is associated with aberrant B-cell function and type I interferon production in systemic lupus erythematosus. <i>Lupus</i> , 2021, 30, 2054-2065.	0.8	3
230	Epigallocatechin gallate exhibits anti-inflammatory effects in a human interface dermatitis model—implications for therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 144-153.	1.3	8
232	Abnormalities of the type I interferon signaling pathway in lupus autoimmunity. <i>Cytokine</i> , 2021, 146, 155633.	1.4	24
233	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 817-835.	0.6	62
234	Epigenetics in systemic lupus erythematosus and the integration of molecular pathways. , 2021, , 35-61.		0

#	ARTICLE	IF	CITATIONS
235	Interferon-directed therapies for the treatment of systemic lupus erythematosus: a critical update. <i>Clinical Rheumatology</i> , 2021, 40, 3027-3037.	1.0	6
236	Socioeconomic Impact of SLE: Metrics Utilized in the Determination of Direct and Indirect Costs and Future Directions. , 2021, , 403-410.		0
237	Kidney disease. , 2021, , 471-502.		0
238	Glucocorticoids. , 2021, , 611-622.		0
239	High Disease Severity Among Asians in a US Multiethnic Cohort of Individuals with Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020, , .	1.5	8
240	Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 677-694.	2.9	41
241	Positive results for anifrolumab in phase III SLE trial. <i>Nature Reviews Rheumatology</i> , 2020, 16, 125-125.	3.5	4
242	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	38
243	New therapeutic approaches in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2021, 33, 181-189.	2.0	5
244	Update on the cellular pathogenesis of lupus. <i>Current Opinion in Rheumatology</i> , 2021, 33, 190-196.	2.0	10
247	Immunogenetics in systemic lupus erythematosus: Transitioning from genetic associations to cellular effects. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12894.	1.3	15
248	A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies. <i>F1000Research</i> , 2020, 9, 905.	0.8	16
249	Downregulation of Renal Hsa-miR-127-3p Contributes to the Overactivation of Type I Interferon Signaling Pathway in the Kidney of Lupus Nephritis. <i>Frontiers in Immunology</i> , 2021, 12, 747616.	2.2	6
250	Measurement of specific organ domains in lupus randomized controlled trials: a scoping review. <i>Rheumatology</i> , 2022, 61, 1341-1353.	0.9	4
253	Signaling by the inhibitory receptor CD200R is rewired by type I interferon. <i>Science Signaling</i> , 2021, 14, eabb4324.	1.6	6
254	The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11286.	1.8	24
255	Targeting interferon- $\beta$ in hyperinflammation: opportunities and challenges. <i>Nature Reviews Rheumatology</i> , 2021, 17, 678-691.	3.5	57
256	JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 911-925.	1.5	57

#	ARTICLE	IF	CITATIONS
257	Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus. <i>Mediterranean Journal of Rheumatology</i> , 2019, 31, 87.	0.3	2
258	Treatment of systemic lupus erythematosus. <i>Australian Prescriber</i> , 2020, 43, 85-90.	0.5	8
259	Emerging Therapies for Cutaneous Lupus Erythematosus. , 2020, 105, .		2
260	TLR Stimulation Produces IFN- $\hat{I}^2$ as the Primary Driver of IFN Signaling in Nonlymphoid Primary Human Cells. <i>ImmunoHorizons</i> , 2020, 4, 332-338.	0.8	2
262	Diagnosis and Treatment of Diffuse Connective Tissue Diseases. <i>The Japanese Journal of Rehabilitation Medicine</i> , 2020, 57, 686-692.	0.0	0
263	New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 537-546.	0.2	7
264	Interferon Lambda Regulates Cellular and Humoral Immunity in Pristane-Induced Lupus. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11747.	1.8	4
265	Plasmacytoid dendritic cell activation is dependent on coordinated expression of distinct amino acid transporters. <i>Immunity</i> , 2021, 54, 2514-2530.e7.	6.6	28
266	Smoking associates with increased BAFF and decreased interferon- $\hat{I}^3$ levels in patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2021, 8, e000537.	1.1	12
267	Lupus Eritematoso SistÃmico: relaÃo entre os diferentes tratamentos e evoluÃo clÃnica. , 2020, 99, 573-580.	0.0	4
268	The dawn of a new era of therapies in systemic lupus erythematosus. <i>Rheumatology and Immunology Research</i> , 2020, 1, 31-37.	0.2	3
269	Safety, Tolerability, and Pharmacokinetics of PF06823859, an Anti-Interferon $\hat{I}^2$ Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 307-316.	0.8	3
270	Dendritic Cells. , 2022, , 110-117.		1
272	Internal Medicine, 2020, 109, 112b-112b.	0.0	0
273	Erythrocyte-derived mitochondria: an unexpected interferon inducer in lupus. <i>Trends in Immunology</i> , 2021, 42, 1054-1056.	2.9	4
275	Increasing Ancestral Diversity in Lupus Trials. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 713-722.	0.8	3
276	Cutaneous Lupus Erythematosus: Current and Future Pathogenesis-Directed Therapies. <i>Yale Journal of Biology and Medicine</i> , 2020, 93, 81-95.	0.2	12
277	Getting Under the Skin: Targeting Cutaneous Autoimmune Disease. <i>Yale Journal of Biology and Medicine</i> , 2020, 93, 197-206.	0.2	2

#	ARTICLE	IF	CITATIONS
278	The role of Stim1 in the progression of lupus nephritis in mice. International Journal of Clinical and Experimental Pathology, 2020, 13, 3021-3032.	0.5	0
279	Balancing Strategies: GC and GILZ Axis. , 2021, , 161-178.		0
280	Synthesis and structure-activity relationship studies of 1,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 1 (JAK1) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2022, 55, 128451.	1.0	1
281	Coordination of retrotransposons and type I interferon with distinct interferon pathways in dermatomyositis, systemic lupus erythematosus and autoimmune blistering disease. Scientific Reports, 2021, 11, 23146.	1.6	10
282	Actualit�s dans la n�phrite lupique. Bulletin De L'Academie Nationale De Medecine, 2021, 206, 23-23.	0.0	1
283	Targeted Delivery of Chloroquine to Antigen-Presenting Cells Enhances Inhibition of the Type I Interferon Response. ACS Biomaterials Science and Engineering, 2021, 7, 5666-5677.	2.6	4
284	Deconvoluting the heterogeneity of SLE: The contribution of ancestry. Journal of Allergy and Clinical Immunology, 2022, 149, 12-23.	1.5	11
285	Type III Interferons: Emerging Roles in Autoimmunity. Frontiers in Immunology, 2021, 12, 764062.	2.2	13
287	The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease. Lancet Rheumatology, The, 2022, 4, e61-e72.	2.2	9
290	Lupus Academy: Keeping Education Live, Virtually. Journal of European CME, 2021, 10, 2014041.	0.6	3
291	Internal Medicine, 2020, 109, 1748-1758.	0.0	0
292	Immunosuppression in Rheumatologic and Auto-immune Disease. Handbook of Experimental Pharmacology, 2021, , 181-208.	0.9	2
294	B Cell Activation and Plasma Cell Differentiation Are Promoted by IFN-� in Systemic Lupus Erythematosus. Journal of Immunology, 2021, 207, 2660-2672.	0.4	12
295	Treatment of lupus: more options after a long wait. Annals of the Rheumatic Diseases, 2022, 81, 753-756.	0.5	5
297	The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Science Translational Medicine, 2022, 14, eabl8124.	5.8	143
298	Lung Inflammation in STING-Associated Vasculopathy with Onset in Infancy (SAVI). Cells, 2022, 11, 318.	1.8	28
299	Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus. Expert Opinion on Biological Therapy, 2022, 22, 499-507.	1.4	6
301	Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nature Reviews Rheumatology, 2022, 18, 133-145.	3.5	193

#	ARTICLE	IF	CITATIONS
302	Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Literature Review of the Last Decade. <i>Brain Sciences</i> , 2022, 12, 192.	1.1	12
304	Systemic lupus erythematosus – Are children miniature adults?. <i>Clinical Immunology</i> , 2022, 234, 108907.	1.4	14
305	Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. <i>Nature Reviews Rheumatology</i> , 2022, 18, 146-157.	3.5	55
306	The effect of Omega-3 fatty acid supplementation in systemic lupus erythematosus patients: A systematic review. <i>Lupus</i> , 2022, 31, 287-296.	0.8	4
307	Diagnostic, predictive and prognostic biomarkers in systemic lupus erythematosus: current insights. <i>Current Opinion in Rheumatology</i> , 2022, 34, 139-149.	2.0	15
308	Type I Interferons in Autoimmunity. <i>Journal of Investigative Dermatology</i> , 2022, 142, 793-803.	0.3	21
309	Applying Early Intervention Strategies to Autoimmune Skin Diseases. Is the Window of Opportunity Preclinical? A Dermato-Rheumatology Perspective. <i>Journal of Investigative Dermatology</i> , 2022, 142, 944-950.	0.3	7
310	Who will respond to type I interferon receptor blockade in SLE?. <i>Lancet Rheumatology</i> , The, 2022, , .	2.2	0
311	Glucocorticoids and natural killer cells: A suppressive relationship. <i>Biochemical Pharmacology</i> , 2022, 198, 114930.	2.0	6
312	Systemic lupus erythematosus as a genetic disease. <i>Clinical Immunology</i> , 2022, 236, 108953.	1.4	18
313	Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 496-506.	0.5	87
314	The Efficacy and Safety of Anifrolumab in Japanese Patients With Systemic Lupus Erythematosus: TULIP-2 Subanalysis. <i>Modern Rheumatology</i> , 2022, , .	0.9	3
315	Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2022, , .	1.3	5
316	Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. <i>Lancet Rheumatology</i> , The, 2022, 4, e282-e292.	2.2	34
317	Anti-RNP antibodies are associated with the interferon gene signature but not decreased complement levels in SLE. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 632-643.	0.5	17
319	Targeted Immunotherapy for Autoimmune Disease. <i>Immune Network</i> , 2022, 22, e9.	1.6	46
321	A glimpse into the future of systemic lupus erythematosus. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210867.	1.2	14
322	COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. <i>Nature Reviews Rheumatology</i> , 2022, 18, 191-204.	3.5	105

#	ARTICLE	IF	CITATIONS
323	Biologic Agents and Other Emerging Therapies for Childhood SLE. <i>Pediatric Annals</i> , 2022, 51, e63-e71.	0.3	1
324	Expert Perspective: An Approach to Refractory Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 915-926.	2.9	14
325	Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval. <i>ACR Open Rheumatology</i> , 2022, 4, 486-491.	0.9	23
326	Type I Interferons in Systemic Lupus Erythematosus: A Journey from Bench to Bedside. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2505.	1.8	21
327	The Role of Clinical Features and Serum Biomarkers in Identifying Patients with Incomplete Lupus Erythematosus at Higher Risk of Transitioning to Systemic Lupus Erythematosus: Current Perspectives. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 1133-1145.	1.6	5
328	SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies. <i>RMD Open</i> , 2022, 8, e001934.	1.8	16
329	Insights Gained and Future Outlook From scRNAseq Studies in Autoimmune Rheumatic Diseases. <i>Frontiers in Immunology</i> , 2022, 13, 849050.	2.2	2
330	Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis. <i>Lupus Science and Medicine</i> , 2022, 9, e000625.	1.1	24
331	Cutaneous Lupus Erythematosus and Dermatomyositis: Utilizing Assessment Tools for Treatment Efficacy. <i>Journal of Investigative Dermatology</i> , 2022, 142, 936-943.	0.3	3
332	Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab. <i>Lancet Rheumatology</i> , The, 2022, 4, e198-e207.	2.2	7
333	Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China. <i>Frontiers in Immunology</i> , 2022, 13, 825367.	2.2	20
334	Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. <i>Lupus Science and Medicine</i> , 2022, 9, e000634.	1.1	18
335	Immune cell multiomics analysis reveals contribution of oxidative phosphorylation to B-cell functions and organ damage of lupus. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 845-853.	0.5	20
336	Animal models of systemic lupus erythematosus and their applications in drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 489-500.	2.5	1
337	CD11b agonists offer a novel approach for treating lupus nephritis. <i>Translational Research</i> , 2022, 245, 41-54.	2.2	9
338	Transcriptomic profiling of blood from autoimmune hepatitis patients reveals potential mechanisms with implications for management. <i>PLoS ONE</i> , 2022, 17, e0264307.	1.1	3
339	“Not at target”: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study. <i>Arthritis Research and Therapy</i> , 2022, 24, 70.	1.6	17
340	Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 951-961.	0.5	38

#	ARTICLE	IF	CITATIONS
341	The Relationship between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus. <i>Journal of Clinical Pharmacology</i> , 2022, , .	1.0	1
342	Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2022, 386, 1034-1045.	13.9	48
343	A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus. <i>Rheumatology and Therapy</i> , 2022, 9, 781-802.	1.1	9
344	Causal cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two Phase 3 trials. <i>Rheumatology</i> , 2022, 61, 4731-4740.	0.9	2
345	Type I interferon-related kidney disorders. <i>Kidney International</i> , 2022, 101, 1142-1159.	2.6	21
346	Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab. <i>Rheumatology</i> , 2022, 61, 4905-4909.	0.9	13
347	Cell type-specific mechanistic target of rapamycin-dependent distortion of autophagy pathways in lupus nephritis. <i>Translational Research</i> , 2022, 245, 55-81.	2.2	14
348	New Treatment Options in Lupus Nephritis. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2022, 70, 11.	1.0	3
349	Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus. <i>Science</i> , 2022, 376, eabf1970.	6.0	156
350	Endothelial function and endothelial progenitor cells in systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2022, 18, 286-300.	3.5	18
351	Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 1106-1120.	1.0	5
352	High Systemic Type I Interferon Activity Is Associated With Active Class III/IV Lupus Nephritis. <i>Journal of Rheumatology</i> , 2022, 49, 388-397.	1.0	11
353	Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. <i>Paediatric Drugs</i> , 2022, 24, 13-27.	1.3	5
354	Neuropsychiatric Systemic Lupus Erythematosus in Older Adults: Diagnosis and Management. <i>Drugs and Aging</i> , 2022, 39, 129-142.	1.3	4
355	Differential Changes in ACPA Fine Specificity and Gene Expression in a Randomized Trial of Abatacept and Adalimumab in Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2022, 9, 391-409.	1.1	3
356	SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases. <i>Journal of Translational Autoimmunity</i> , 2022, 5, 100154.	2.0	12
357	Current Status and Future Challenges in the Treatment of Rheumatic Diseases. <i>Frontiers in Drug Safety and Regulation</i> , 2022, 2, .	0.5	0
358	Genetics and epigenetics of autoimmune thyroid diseases: Translational implications. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2023, 37, 101661.	2.2	20

#	ARTICLE	IF	CITATIONS
359	GDF15 Suppresses Lymphoproliferation and Humoral Autoimmunity in a Murine Model of Systemic Lupus Erythematosus. <i>Journal of Innate Immunity</i> , 2022, 14, 673-689.	1.8	9
360	CDK inhibitor Palbociclib targets STING to alleviate autoinflammation. <i>EMBO Reports</i> , 2022, 23, e53932.	2.0	24
365	Tailored treatment strategies and future directions in systemic lupus erythematosus. <i>Rheumatology International</i> , 2022, 42, 1307-1319.	1.5	5
366	Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1085-1095.	0.5	26
367	A Review of Lupus Nephritis. <i>journal of applied laboratory medicine, The</i> , 2022, 7, 1450-1467.	0.6	9
368	Machine learning reveals distinct gene signature profiles in lesional and nonlesional regions of inflammatory skin diseases. <i>Science Advances</i> , 2022, 8, eabn4776.	4.7	15
369	Lupus Nephritis: Improving Treatment Options. <i>Drugs</i> , 2022, 82, 735-748.	4.9	10
370	A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 867-885.	1.4	12
371	Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 765-777.	0.6	14
372	Interferon blockade in lupus: effects on antiviral immunity. <i>Nature Reviews Nephrology</i> , 2022, , .	4.1	4
373	Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. <i>Lancet Rheumatology, The</i> , 2022, 4, e441-e449.	2.2	17
374	Belimumab for systemic lupus erythematosus – Focus on lupus nephritis. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2072143.	1.4	6
375	Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 962-969.	0.5	15
376	Role of interleukin-6 and interferon- $\gamma$ in systemic lupus erythematosus: A case-control study and meta-analysis. <i>Lupus</i> , 2022, 31, 1094-1103.	0.8	7
377	Specific in situ inflammatory states associate with progression to renal failure in lupus nephritis. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	21
378	Novel microRNA biomarkers of systemic lupus erythematosus in plasma: miR-124-3p and miR-377-3p. <i>Clinical Biochemistry</i> , 2022, 107, 55-61.	0.8	10
379	Gypenosides regulate autophagy through Sirt1 pathway and the anti-inflammatory mechanism of mitochondrial autophagy in systemic lupus erythematosus. <i>Bioengineered</i> , 2022, 13, 13384-13397.	1.4	1
380	Lessons From Transcriptome Analysis of Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	3

#	ARTICLE	IF	CITATIONS
381	Dysregulation of the cGAS-STING Pathway in Monogenic Autoinflammation and Lupus. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
382	The Genetic Landscape of Cutaneous Lupus Erythematosus. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
383	Understanding the Concept of Pre-Clinical Autoimmunity: Prediction and Prevention of Systemic Lupus Erythematosus: Identifying Risk Factors and Developing Strategies Against Disease Development. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
388	Longitudinal Immune Cell Profiling in Patients With Early Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2022, 74, 1808-1821.	2.9	18
389	Rapid Response of Refractory Systemic Lupus Erythematosus Skin Manifestations to Anifrolumab—A Case-Based Review of Clinical Trial Data Suggesting a Domain-Based Therapeutic Approach. <i>Journal of Clinical Medicine</i> , 2022, 11, 3449.	1.0	8
390	Role of the cGAS-STING pathway in systemic and organ-specific diseases. <i>Nature Reviews Nephrology</i> , 2022, 18, 558-572.	4.1	59
391	CD8+ T-Cells in Juvenile-Onset SLE: From Pathogenesis to Comorbidities. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
392	Belimumab: A BAFF-specific Inhibitor for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis. , 2022, 1, 32.		0
393	Anifrolumab: An Inhibitor of Type I Interferon for the Treatment of Patients with Systemic Lupus Erythematosus. , 2022, 1, 29.		0
394	Pharmacological actions of anifrolumab (Saphnelo <sup>®</sup> ) and clinical trial results as a treatment for systemic lupus erythematosus. <i>Folia Pharmacologica Japonica</i> , 2022, 157, 271-279.	0.1	0
395	Could a simple biomarker as neutrophil-to-lymphocyte ratio reflect complex processes orchestrated by neutrophils?. <i>Journal of Translational Autoimmunity</i> , 2023, 6, 100159.	2.0	7
396	Comparisons between US norm-based two-component and Japanese norm-based three-component SF-36 summary scores in systemic lupus erythematosus patients. <i>Modern Rheumatology</i> , 0, , .	0.9	0
397	Dendritic cells in systemic lupus erythematosus: From pathogenesis to therapeutic applications. <i>Journal of Autoimmunity</i> , 2022, 132, 102856.	3.0	23
398	Systemic Lupus Erythematosus: New Diagnostic and Therapeutic Approaches. <i>Annual Review of Medicine</i> , 2023, 74, 339-352.	5.0	34
399	Anifrolumab for treatment of refractory cutaneous lupus erythematosus. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 1998-2001.	0.6	21
401	Recent advances in cutaneous lupus. <i>Journal of Autoimmunity</i> , 2022, 132, 102865.	3.0	5
402	Anifrolumab in systemic lupus erythematosus: a profile of its use. <i>Drugs and Therapy Perspectives</i> , 0, , .	0.3	0
403	Autoantibodies against IFN $\beta$ in patients with systemic lupus erythematosus and susceptibility for infection: a retrospective case-control study. <i>Scientific Reports</i> , 2022, 12, .	1.6	6

#	ARTICLE	IF	CITATIONS
404	Emerging Therapies in Cutaneous Lupus Erythematosus. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
405	The effect of systemic lupus erythematosus on sexual function in women: an updated meta-analysis based on cross-sectional studies. <i>Advances in Rheumatology</i> , 2022, 62, .	0.8	3
406	GILZ regulates type I interferon release and sequesters STAT1. <i>Journal of Autoimmunity</i> , 2022, 131, 102858.	3.0	5
407	The promise of precision medicine in rheumatology. <i>Nature Medicine</i> , 2022, 28, 1363-1371.	15.2	24
408	Identification of key interferon-stimulated genes for indicating the condition of patients with systemic lupus erythematosus. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
409	Cross-species transcriptome analysis for early detection and specific therapeutic targeting of human lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1409-1419.	0.5	9
410	Abnormalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies. <i>Journal of Autoimmunity</i> , 2022, 132, 102870.	3.0	39
411	Recent Advances in SLE Treatment Including Biologic Therapies. , 0, , .		0
412	Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2022, 387, 321-331.	13.9	47
413	Safety and Efficacy of Switching Immunosuppressive Drugs for Maintenance Treatment in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study. <i>Modern Rheumatology</i> , 0, , .	0.9	0
414	Current concepts of photosensitivity in cutaneous lupus erythematosus. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
415	Distinct transcriptome architectures underlying lupus establishment and exacerbation. <i>Cell</i> , 2022, 185, 3375-3389.e21.	13.5	33
416	Neuropsychiatric lupus erythematosus: Focusing on autoantibodies. <i>Journal of Autoimmunity</i> , 2022, 132, 102892.	3.0	2
417	Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a <i>post hoc</i> analysis of the TULIP-1 and TULIP-2 trials. <i>Rheumatology</i> , 2023, 62, 1526-1534.	0.9	6
418	Differentiating central nervous system demyelinating disorders: The role of clinical, laboratory, imaging characteristics and peripheral blood type I interferon activity. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6
419	Neonatal BCG vaccination is associated with a long-term DNA methylation signature in circulating monocytes. <i>Science Advances</i> , 2022, 8, .	4.7	29
420	Experience with type I interferon inhibitor in systemic lupus erythematosus. <i>Sovremennaya Revmatologiya</i> , 2022, 16, 69-73.	0.1	0
421	What is new in the treatment of Systemic Lupus Erythematosus?. <i>Vnitri Lekarstvi</i> , 2022, 68, 273-278.	0.1	0

#	ARTICLE	IF	CITATIONS
422	Progress in the Pathogenesis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus. <i>Journal of Clinical Medicine</i> , 2022, 11, 4955.	1.0	7
423	Lupus nephritis: new progress in diagnosis and treatment. <i>Journal of Autoimmunity</i> , 2022, 132, 102871.	3.0	37
424	Systemic lupus erythematosus: history and modernity. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2022, 60, 397-412.	0.2	11
425	Progress toward Better Treatment of Lupus. <i>New England Journal of Medicine</i> , 2022, 387, 939-940.	13.9	1
427	Cutaneous Involvement in Systemic Lupus Erythematosus: A Review for the Rheumatologist. <i>Journal of Rheumatology</i> , 2023, 50, 27-35.	1.0	15
428	Do biological agents improve health-related quality of life in patients with systemic lupus erythematosus? Results from a systematic search of the literature. <i>Autoimmunity Reviews</i> , 2022, 21, 103188.	2.5	9
429	IL-4 receptor blockade is a global repressor of naïve B cell development and responses in a dupilumab-treated patient. <i>Clinical Immunology</i> , 2022, 244, 109130.	1.4	8
430	8. Current Patient Assessments and Therapeutic Strategies in Rheumatic Disease. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 1958-1964.	0.0	0
431	Infections Associated with Systemic Lupus Erythematosus: Tackling Two Devils in the Deep Blue Sea. <i>Indian Journal of Rheumatology</i> , 2023, 18, S3-S11.	0.2	0
432	Real-Life Outcome of Lupus Nephritis with Current Therapies: Study Protocol of a Multicentre Observational Study. <i>Mediterranean Journal of Rheumatology</i> , 2022, 33, 263.	0.3	0
433	Clinical significance of interleukin-36 alpha and gamma in systemic lupus erythematosus patients: Potential relation to disease activity and subclinical arthritis. <i>Egyptian Rheumatologist</i> , 2023, 45, 33-37.	0.5	2
434	Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
435	B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	13
436	An evaluation of anifrolumab for use in adults with systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 1095-1106.	1.3	1
437	Identification and functional analysis of shared gene signatures between systemic lupus erythematosus and Sjögren's syndrome. <i>Rheumatology &amp; Autoimmunity</i> , 2022, 2, 150-158.	0.3	1
438	Ianalumab in Sjögren's syndrome: what can we learn from lupus trials?. <i>Lancet, The</i> , 2022, 400, 807-808.	6.3	0
439	Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long-Term Clinical Outcomes: A Five-Year Prospective Study. <i>Arthritis and Rheumatology</i> , 2023, 75, 401-410.	2.9	2
440	Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3

#	ARTICLE	IF	CITATIONS
441	Diversity of NF- $\kappa$ B signalling and inflammatory heterogeneity in Rheumatic Autoimmune Disease. <i>Seminars in Immunology</i> , 2021, 58, 101649.	2.7	6
442	Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2022, 387, 894-904.	13.9	37
443	Urine proteomic insights from the belimumab in lupus nephritis trial. <i>Lupus Science and Medicine</i> , 2022, 9, e000763.	1.1	3
444	Residual disease activity and treatment intensification in systemic lupus erythematosus: A cross-sectional study to quantify the need for new therapies. <i>Lupus</i> , 0, , 096120332211297.	0.8	0
445	SLE stratification based on BAFF and IFN-I bioactivity for biologics and implications of BAFF produced by glomeruli in lupus nephritis. <i>Rheumatology</i> , 2023, 62, 1988-1997.	0.9	11
446	Targeted Therapies for Systemic Lupus Erythematosus (SLE): A Critical Appraisal. , 0, , .		0
447	Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 0, Volume 15, 1815-1831.	0.8	3
448	SIGLEC-1 in Systemic Sclerosis: A Useful Biomarker for Differential Diagnosis. <i>Pharmaceuticals</i> , 2022, 15, 1198.	1.7	10
449	Estado actual y retos futuros en el tratamiento de las enfermedades reumáticas. <i>Revista Del Hospital Italiano De Buenos Aires</i> , 2022, 42, 158-162.	0.0	0
450	Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. <i>Nature Medicine</i> , 2022, 28, 2124-2132.	15.2	244
452	New insights in systemic lupus erythematosus: From regulatory T cells to CAR-T-cell strategies. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 1289-1301.	1.5	10
453	Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit. <i>Current Opinion in Rheumatology</i> , 2022, 34, 357-364.	2.0	12
454	Emerging concepts of type I interferons in SLE pathogenesis and therapy. <i>Nature Reviews Rheumatology</i> , 0, , .	3.5	22
455	Advances in lupus therapeutics: Achieving sustained control of the type I interferon pathway. <i>Current Opinion in Pharmacology</i> , 2022, 67, 102291.	1.7	1
456	II. Appropriate Immunosuppressive Therapy in Clinical Practice of Systemic Lupus Erythematosus. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 2166-2172.	0.0	0
457	Plasmacytoid Dendritic Cells in Autoimmunity. , 2022, , 85-106.		0
458	Therapeutic Targeting of Plasmacytoid Dendritic Cells. , 2022, , 147-160.		0
459	Treatment management of patients with systemic lupus erythematosus: a delphi consensus analysis. <i>Global &amp; Regional Health Technology Assessment</i> , 0, 9, 123-132.	0.2	0

#	ARTICLE	IF	CITATIONS
460	Novel and emerging treatment strategies for lupus nephritis. Expert Review of Clinical Pharmacology, 2022, 15, 1283-1292.	1.3	5
461	Dampened Inflammation and Improved Survival After CXCL5 Administration in Murine Lupus via Myeloid and Neutrophil Pathways. Arthritis and Rheumatology, 2023, 75, 553-566.	2.9	6
463	Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium. Journal of Clinical Medicine, 2022, 11, 6016.	1.0	8
464	Targeting type I interferon (IFN) signalling in patients with RA with a high type I IFN gene signature. RMD Open, 2022, 8, e002525.	1.8	2
465	Diagnosis and Management of Cutaneous Manifestations of Autoimmune Connective Tissue Diseases. Clinical, Cosmetic and Investigational Dermatology, 0, Volume 15, 2285-2312.	0.8	1
466	Defining the Role of Monocytes in Sjögren's Syndrome. International Journal of Molecular Sciences, 2022, 23, 12765.	1.8	7
467	<sc>mTORC2</sc> contributes to systemic autoimmunity. Immunology, 2023, 168, 554-568.	2.0	1
468	COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection. PLoS Genetics, 2022, 18, e1010253.	1.5	12
469	<sc>First-in-human</sc> study of deucravacitinib: A selective, potent, allosteric <sc>small-molecule</sc> inhibitor of tyrosine kinase 2. Clinical and Translational Science, 2023, 16, 151-164.	1.5	19
470	Macrophages in Lupus Nephritis: Exploring a potential new therapeutic avenue. Autoimmunity Reviews, 2022, 21, 103211.	2.5	16
471	TGF- $\beta$ 3 in differentiation and function of Tph-like cells and its relevance to disease activity in patients with systemic lupus erythematosus. Rheumatology, 2023, 62, 2464-2474.	0.9	4
472	Single-cell profiling to transform immunotherapy usage and target discovery in immune-mediated inflammatory diseases. Frontiers in Immunology, 0, 13, .	2.2	1
474	Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study. Lancet Rheumatology, The, 2022, 4, e831-e841.	2.2	3
475	Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <sc>II</sc>, Randomized, <sc>Double-blind</sc>, <sc>Placebo-controlled</sc> Trial. Arthritis and Rheumatology, 2023, 75, 242-252.	2.9	51
477	Single-cell transcriptome profiling and chromatin accessibility reveal an exhausted regulatory CD4+ T cell subset in systemic lupus erythematosus. Cell Reports, 2022, 41, 111606.	2.9	12
478	A case of Rowell syndrome with excellent improvement following anifrolumab. JAAD Case Reports, 2023, 31, 27-30.	0.4	5
479	The expression of Ets-1 and Fli-1 is associated with interferon-inducible genes in peripheral blood mononuclear cells from Japanese patients with systemic lupus erythematosus. Medicine (United Tj ETQq0 0 0 rgBT, Overlock 10 Tf 50 9		
480	A Randomized, <sc>Placebo-controlled</sc> Phase <sc>III</sc> Extension Trial of the <sc>Long-term</sc> Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2023, 75, 253-265.	2.9	33

#	ARTICLE	IF	CITATIONS
481	Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE. <i>Lupus Science and Medicine</i> , 2022, 9, e000808.	1.1	5
482	Disease trajectory of <scp>SLE</scp> clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled <scp>patientâ€level</scp> placebo (<scp>Standardâ€ofâ€Care</scp>) data to enable <scp>modelâ€informed</scp> drug development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 180-195.	1.3	5
483	Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. <i>Journal of Comparative Effectiveness Research</i> , 2023, 12, .	0.6	1
484	Letter to the Editor: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. <i>Journal of Comparative Effectiveness Research</i> , 2023, 12, .	0.6	1
486	The efficacy and safety of telitacept for the treatment of systemic lupus erythematosus: a real life observational study. <i>Lupus</i> , 2023, 32, 94-100.	0.8	13
487	Interferons and systemic lupus erythematosus: Pathogenesis, clinical features, and treatments in interferon-driven disease. <i>Modern Rheumatology</i> , 0, , .	0.9	5
488	Interferon in systemic lupus erythematosusâ€”A halfway between monogenic autoinflammatory and autoimmune disease. <i>Heliyon</i> , 2022, 8, e11741.	1.4	2
489	Type 1 interferon suppresses expression and glucocorticoid induction of glucocorticoid-induced leucine zipper (GILZ). <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
490	Unraveling the Link between Interferon-Î± and Systemic Lupus Erythematosus: From the Molecular Mechanisms to Target Therapies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15998.	1.8	4
491	Improving measures of disease activity in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2023, 19, 193-202.	1.3	3
493	Serum IFNÎ±2 levels are associated with disease activity and outperform IFN-I gene signature in a longitudinal childhood-onset SLE cohort. <i>Rheumatology</i> , 0, , .	0.9	1
494	Differences and similarities in cytokine profiles of macrophage activation syndrome in systemic lupus erythematosus and adult-onset Stillâ€™s disease. <i>Clinical and Experimental Medicine</i> , 2023, 23, 3407-3416.	1.9	1
495	Targeting type I interferons in systemic lupus erythematosus. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
496	Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials. <i>Lupus Science and Medicine</i> , 2023, 10, e000761.	1.1	5
497	Clinical spectrum and currently available treatment of type I interferonopathyâ€”GoutiÃˆres syndrome. <i>World Journal of Pediatrics</i> , 2023, 19, 635-643.	0.8	1
498	New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review. <i>Joint Bone Spine</i> , 2023, 90, 105523.	0.8	18
499	Nucleic Acid Sensing and Systemic Lupus Erythematosus: The Danger of Self. <i>Journal of Immunology</i> , 2022, 209, 431-433.	0.4	0
500	Ring Finger Protein 215 Negatively Regulates Type I IFN Production via Blocking NF-Î²B p65 Activation. <i>Journal of Immunology</i> , 2022, 209, 2012-2021.	0.4	3

#	ARTICLE	IF	CITATIONS
501	ANCA-Associated Vasculitis, Anti-GBM Disease, and Lupus Nephritis. Nephrology Self-assessment Program: NephSAP, 2022, 21, 364-382.	3.0	0
502	Actualit� du traitement du lupus en 2022. , 2022, , 19-26.		0
503	Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022. Annals of the Rheumatic Diseases, 2023, 82, 594-598.	0.5	6
504	Relationships between Type 1 interferon signatures and clinical features of the new-onset lupus patients in Japan. Modern Rheumatology, 2024, 34, 346-351.	0.9	2
505	Is there an increased risk of severe COVID-19 among patients with systemic lupus erythematosus treated with anifrolumab?. Lupus, 2023, 32, 453-455.	0.8	2
506	Povetacicept, an Enhanced Dual <scp>APRIL</scp>/<scp>BAFF</scp> Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases. Arthritis and Rheumatology, 2023, 75, 1187-1202.	2.9	4
508	Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2023, 82, 639-645.	0.5	13
509	Biomarker-driven development of new therapies for autoimmune diseases: current status and future promises. Expert Review of Clinical Immunology, 2023, 19, 305-314.	1.3	4
510	Safety and Efficacy of Anifrolumab for Systemic Lupus Erythematosus: Network Meta-analysis. American Journal of Therapeutics, 0, Publish Ahead of Print, .	0.5	0
511	Cytokines and Cytokine Receptors. , 2023, , 186-214.		1
512	Rheumatic diseases: From bench to bedside. , 2023, , 27-46.		0
513	Heterogeneity of antibody-secreting cells infiltrating autoimmune tissues. Frontiers in Immunology, 0, 14, .	2.2	0
514	Performance of systemic lupus erythematosus responder index for detecting <scp>clinician-rated</scp> responders in patients with active systemic lupus erythematosus. International Journal of Rheumatic Diseases, 2023, 26, 667-672.	0.9	2
515	Lupus Interference With B Cell Tolerance Across the Developmental Continuum. Arthritis and Rheumatology, 2023, 75, 1503-1505.	2.9	0
516	Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. International Journal of Molecular Sciences, 2023, 24, 6578.	1.8	8
517	Assessment of Clinical Response to Anifrolumab in Patients With Refractory Discoid Lupus Erythematosus. JAMA Dermatology, 2023, 159, 560.	2.0	15
518	UBE2L3 regulates TLR7-induced B cell autoreactivity in Systemic Lupus Erythematosus. Journal of Autoimmunity, 2023, 136, 103023.	3.0	7
519	Toll-Like Receptor 3 Mediates Aortic Stenosis Through a Conserved Mechanism of Calcification. Circulation, 2023, 147, 1518-1533.	1.6	5

#	ARTICLE	IF	CITATIONS
520	Kunxian capsule alleviates renal damage by inhibiting the JAK1/STAT1 pathway in lupus nephritis. <i>Journal of Ethnopharmacology</i> , 2023, 310, 116349.	2.0	2
521	Biologics and JAK inhibitors for the treatment of monogenic systemic autoinflammatory diseases in children. <i>Journal of Allergy and Clinical Immunology</i> , 2023, 151, 607-618.	1.5	6
522	NLRP12 is an innate immune checkpoint for repressing IFN signatures and attenuating lupus nephritis progression. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	7
523	Systemischer Lupus erythematosus: Strukturierte Diagnostik – Erfolg versprechende Therapie. , 0, , .		0
524	Breaking down the cellular responses to type I interferon neurotoxicity in the brain. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	10
526	Autoantibody repertoire characterization provides insight into the pathogenesis of monogenic and polygenic autoimmune diseases. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
527	Recent advance in management of herpes simplex in Japan. <i>Journal of Dermatology</i> , 2023, 50, 299-304.	0.6	2
528	Relationship of systemic type I interferon activity with clinical phenotypes, disease activity, and damage accrual in systemic lupus erythematosus in treatment-naïve patients: a retrospective longitudinal analysis. <i>Arthritis Research and Therapy</i> , 2023, 25, .	1.6	6
529	Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus. <i>Lancet Rheumatology</i> , The, 2023, 5, e151-e165.	2.2	3
530	Anti-dsDNA IgE induces IL-4 production from basophils, potentially involved in B-cell differentiation in systemic lupus erythematosus. <i>Rheumatology</i> , 2023, 62, 3480-3489.	0.9	1
531	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). <i>Lancet</i> , The, 2023, 401, 1001-1010.	6.3	44
532	SLE-BRAVE I and II. <i>Lancet</i> , The, 2023, 401, 972-973.	6.3	1
533	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). <i>Lancet</i> , The, 2023, 401, 1011-1019.	6.3	53
534	RheumMadness: Creating an Online Community of Inquiry in Rheumatology. <i>Arthritis Care and Research</i> , 0, , .	1.5	1
535	Systemic Lupus Erythematosus Pathogenesis: Interferon and Beyond. <i>Annual Review of Immunology</i> , 2023, 41, 533-560.	9.5	28
536	Treatment of lupus nephritis: consensus, evidence and perspectives. <i>Nature Reviews Rheumatology</i> , 2023, 19, 227-238.	3.5	17
537	Immunopathogenesis of systemic lupus erythematosus. , 2023, , 265-292.		0
538	Challenges in systemic lupus erythematosus: From bench to bedside. , 2023, , 293-331.		1

#	ARTICLE	IF	CITATIONS
539	Similarity and difference between systemic lupus erythematosus and NZB/W F1 mice by multi-omics analysis. <i>Modern Rheumatology</i> , 2024, 34, 359-368.	0.9	0
540	Rapid efficacy of anifrolumab in refractory cutaneous lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2023, 89, 171-173.	0.6	11
541	2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 754-762.	0.5	9
542	Gut viruses in the pathogenesis of systemic lupus erythematosus. <i>Science Bulletin</i> , 2023, 68, 664-665.	4.3	2
543	Genetics and epigenetics of primary Sjögren syndrome: implications for future therapies. <i>Nature Reviews Rheumatology</i> , 2023, 19, 288-306.	3.5	20
544	Combination strategies for lupus nephritis: facts and controversies. <i>Expert Review of Clinical Immunology</i> , 2023, 19, 527-536.	1.3	2
545	Disruption of endosomal trafficking with EGA alters TLR9 cytokine response in human plasmacytoid dendritic cells. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
546	Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers. <i>British Journal of Dermatology</i> , 2023, 189, 210-218.	1.4	15
547	Corticosteroids reduce pathologic interferon responses by downregulating STAT1 in patients with high-risk COVID-19. <i>Experimental and Molecular Medicine</i> , 2023, 55, 653-664.	3.2	2
548	Bortezomib is efficacious in the treatment of severe childhood-onset neuropsychiatric systemic lupus erythematosus with psychosis: a case series and mini-review of B-cell immunomodulation in antibody-mediated diseases. <i>Clinical Rheumatology</i> , 2023, 42, 1965-1979.	1.0	4
549	Functional Genome Analysis for Immune Cells Provides Clues for Stratification of Systemic Lupus Erythematosus. <i>Biomolecules</i> , 2023, 13, 591.	1.8	3
550	Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline. <i>Drugs</i> , 2023, 83, 479-496.	4.9	2
551	Distinct gene dysregulation patterns herald precision medicine potentiality in systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2023, 136, 103025.	3.0	8
552	Dilemma of immunosuppression and infection risk in systemic lupus erythematosus. <i>Rheumatology</i> , 2023, 62, i22-i29.	0.9	9
553	Rapid response of cutaneous lupus erythematosus to treatment with the type 1 interferon receptor antagonist anifrolumab. <i>British Journal of Dermatology</i> , 2023, 189, 151-153.	1.4	1
554	Lupus Nephritis. , 2023, , 737-763.		0
555	Biologic Response Modifiers. , 2023, , 1089-1101.		0
556	Precision medicine in systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2023, 19, 331-342.	3.5	12

#	ARTICLE	IF	CITATIONS
558	Role of autotaxin in systemic lupus erythematosus. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	0
559	Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren's syndrome: evidence- and practice-based guidance. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	8
561	Lupus erythematoses. <i>JDDG - Journal of the German Society of Dermatology</i> , 2023, 21, 426-431.	0.4	0
562	Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study "Joint and Skin (BeLISS-JS). <i>Journal of Personalized Medicine</i> , 2023, 13, 691.	1.1	1
569	Lupus Nephritis: New and Emerging Biologic and Targeted Therapies. <i>BioDrugs</i> , 2023, 37, 463-475.	2.2	1
575	Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions. <i>American Journal of Clinical Dermatology</i> , 2023, 24, 521-540.	3.3	9
577	Current treatment of systemic lupus erythematosus: a clinician's perspective. <i>Rheumatology International</i> , 2023, 43, 1395-1407.	1.5	6
579	Potential relevance of type I interferon-related biomarkers for the management of polygenic autoimmune rheumatic diseases with childhood onset. <i>Clinical Rheumatology</i> , 2023, 42, 1733-1736.	1.0	1
608	TO MARKET, TO MARKET "2021: MACROMOLECULAR THERAPEUTICS. <i>Medicinal Chemistry Reviews</i> , 0, , 733-805.	0.1	0
627	Atherosclerosis in Systemic Lupus Erythematosus. <i>Current Atherosclerosis Reports</i> , 2023, 25, 819-827.	2.0	2
635	Targeting DORIS Remission and LLDAS in SLE: A Review. <i>Rheumatology and Therapy</i> , 2023, 10, 1459-1477.	1.1	1
647	Case Report: Response of cutaneous lupus lesions in SLE to interferon receptor blockade parallels reduction of interferon score in blood. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
667	21. Arthritis and Other Musculoskeletal Diseases. , 2023, , .		0
697	Vascular damage in systemic lupus erythematosus. <i>Nature Reviews Nephrology</i> , 2024, 20, 251-265.	4.1	1
704	Homeostatic Versus Pathogenic Autoantibodies: Origin, Structure and Effector Functions. , 2024, , 387-412.		0